Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
ImmunityBio, Inc.
IBRX
$2.03
Name : ImmunityBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,999,479,296.00
EPSttm : -0.41
finviz dynamic chart for IBRX
ImmunityBio, Inc.
$2.03
2.40%
$0.05

Float Short %

24.32

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

-0.04

EPS Last/This Y

0.15

EPS This/Next Y

0.16

Price

2.03

Target Price

10.2

Analyst Recom

1

Performance Q

-10.96

Relative Volume

0.98

Beta

Ticker: IBRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20IBRX2.450.230.10243420
2025-10-21IBRX2.430.220.15247737
2025-10-22IBRX2.370.220.16249824
2025-10-23IBRX2.380.220.07251593
2025-10-24IBRX2.460.220.02253907
2025-10-27IBRX2.660.220.08257137
2025-10-28IBRX2.580.220.04261339
2025-10-29IBRX2.410.210.10264870
2025-10-30IBRX2.370.210.22266500
2025-10-31IBRX2.390.210.05268206
2025-11-03IBRX2.260.210.53274659
2025-11-04IBRX2.080.210.21278857
2025-11-05IBRX2.140.210.10281885
2025-11-06IBRX2.120.210.12283297
2025-11-07IBRX2.130.210.81284263
2025-11-10IBRX2.150.212.12286212
2025-11-11IBRX2.130.210.92287028
2025-11-12IBRX2.060.221.29286775
2025-11-13IBRX20.220.33287115
2025-11-14IBRX2.070.210.03287272
2025-11-17IBRX2.030.211.50291753
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20IBRX2.4516.740.1-0.44
2025-10-21IBRX2.4316.745.3-0.44
2025-10-22IBRX2.3616.749.8-0.44
2025-10-23IBRX2.3816.742.3-0.44
2025-10-24IBRX2.4616.738.1-0.44
2025-10-27IBRX2.6516.730.2-0.44
2025-10-28IBRX2.5816.749.3-0.44
2025-10-29IBRX2.4116.755.9-0.44
2025-10-30IBRX2.3616.748.3-0.44
2025-10-31IBRX2.4016.741.1-0.44
2025-11-03IBRX2.2616.754.0-0.44
2025-11-04IBRX2.0716.758.5-0.44
2025-11-05IBRX2.1416.738.6-0.44
2025-11-06IBRX2.1216.737.5-0.44
2025-11-07IBRX2.1316.736.3-0.44
2025-11-10IBRX2.1616.748.5-0.44
2025-11-11IBRX2.14-37.552.7-0.44
2025-11-12IBRX2.06-37.558.4-0.44
2025-11-13IBRX2.00-37.556.5-0.44
2025-11-14IBRX2.07-37.545.5-0.44
2025-11-17IBRX2.03-37.555.6-0.44
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20IBRX0.0017.7274.67
2025-10-21IBRX0.0017.7274.67
2025-10-22IBRX0.0017.7274.67
2025-10-23IBRX0.0017.7274.67
2025-10-24IBRX0.0017.7274.67
2025-10-27IBRX0.0018.0473.80
2025-10-28IBRX0.0018.0473.80
2025-10-29IBRX0.0018.0473.80
2025-10-30IBRX0.0018.0473.80
2025-10-31IBRX0.0018.0473.80
2025-11-03IBRX0.0017.0973.80
2025-11-04IBRX0.0017.0973.80
2025-11-05IBRX0.0017.0973.80
2025-11-06IBRX0.0017.0973.80
2025-11-07IBRX0.0017.0973.80
2025-11-10IBRX0.0016.9123.92
2025-11-11IBRX0.0016.9123.92
2025-11-12IBRX0.0016.9124.32
2025-11-13IBRX0.0016.9124.32
2025-11-14IBRX0.0016.9124.32
2025-11-17IBRX0.0016.2524.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.11

Insider Transactions

Institutional Transactions

16.25

Beta

Average Sales Estimate Current Quarter

35

Average Sales Estimate Next Quarter

30

Fair Value

Quality Score

23

Growth Score

57

Sentiment Score

12

Actual DrawDown %

95

Max Drawdown 5-Year %

Target Price

10.2

P/E

Forward P/E

PEG

P/S

24.22

P/B

P/Free Cash Flow

EPS

-0.42

Average EPS Est. Cur. Y​

-0.44

EPS Next Y. (Est.)

-0.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-422.28

Relative Volume

0.98

Return on Equity vs Sector %

39.5

Return on Equity vs Industry %

54.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

55.6
ImmunityBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 673
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today
news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance
stock history IBRX – ImmunityBio, Inc. invest stock market
stock prices IBRX premarket after hours
ticker IBRX fair value insiders trading